Oramed Pharmaceuticals (ORMP) Invested Capital (2011 - 2026)

Oramed Pharmaceuticals has reported Invested Capital for 16 years, with the latest figure at $238.3 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital rose 70.33% year-over-year to $238.3 million; the trailing twelve-month figure through Mar 2026 stood at $238.3 million (up 70.33% YoY), and the FY2025 full-year result was $199.7 million, up 37.43% from the prior year.
• Invested Capital for Q1 2026 stood at $238.3 million, up from $199.7 million in the prior quarter.
• The five-year high for Invested Capital was $238.3 million in Q1 2026, with the low at $139.9 million in Q1 2025.
• Historically, Invested Capital has averaged $174.5 million across 5 years, with a median of $155.5 million in 2024.
• Annual changes were most pronounced in 2024 — Invested Capital sank 32.05% — and 2026, when it soared 70.33%.
• Oramed Pharmaceuticals' Invested Capital stood at $151.2 million in 2022, then surged by 41.51% to $213.9 million in 2023, then tumbled by 32.05% to $145.3 million in 2024, then soared by 37.43% to $199.7 million in 2025, then grew by 19.29% to $238.3 million in 2026.
• The last three Invested Capital figures came in at $238.3 million (Q1 2026), $199.7 million (Q4 2025), and $202.3 million (Q3 2025), per Business Quant data.